BioMarin Pharmaceutical (BMRN): Assessing Valuation Following Robust Q3 Growth and Upgraded Full-Year Guidance

BioMarin Pharmaceutical (BMRN) grabbed attention after its Q3 update, where it reported solid revenue growth and raised its full-year guidance higher than any of its peers. The big drivers were its PALYNZIQ and VOXZOGO products, each delivering over 20% revenue growth.

See our latest analysis for BioMarin Pharmaceutical.

BioMarin’s latest quarterly momentum has drawn a spotlight, but the share price tells a more cautious story. At $55.52, the 1-year total shareholder return is still down 15%, and the long-term three-year return has lagged by 46%. Short bursts of optimism, like this week’s 5.8% share price gain, have not reversed the broader downward trend, suggesting the market remains in wait-and-see mode despite new product wins and improved guidance.

If BioMarin’s surge in revenue growth has you thinking bigger, it’s worth checking out companies with similarly bold ambitions in life sciences — See the full list for free.

So after a tough stretch for the shares, does BioMarin’s recent momentum signal a buying opportunity, or is the market already anticipating the company’s next phase of growth?

Most Popular Narrative: 39% Undervalued

BioMarin's most widely followed narrative values the stock far above its last closing price, hinting at a disconnect between fundamentals and recent market sentiment. This valuation sets the stage for a closer look at the bullish reasoning behind it.

Expanding global demand, new therapies, and strategic acquisitions strengthen BioMarin's revenue growth, market reach, and future pipeline potential. Operational efficiency, disciplined cost management, and regulatory advantages support sustained profitability and long-term margin stability.

Read the complete narrative.

Curious how BioMarin’s story supports such a high target? It comes down to surprising forecasts for revenue and profit margins, plus big assumptions on future earnings multiples. Discover the full rationale—one key assumption might change everything you think about the company’s prospects.

Result: Fair Value of $90.50 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent competition and potential pipeline setbacks could quickly challenge this undervalued thesis. This keeps uncertainty high for both revenue and profit expectations.

Find out about the key risks to this BioMarin Pharmaceutical narrative.

Build Your Own BioMarin Pharmaceutical Narrative

If you see things differently or want to dig into the data yourself, crafting your own BioMarin story takes less than three minutes. Do it your way

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding BioMarin Pharmaceutical.

Looking for More Smart Opportunities?

Don’t let new breakthroughs pass you by. Thoughtfully hand-pick the stocks that match your goals by browsing powerful screening ideas right now.

• Uncover strong, income-generating plays and seize the chance to tap into steady yield with these 15 dividend stocks with yields > 3% offering consistent payouts above 3%.
• Expand your watchlist to pioneers in artificial intelligence by searching through these 25 AI penny stocks and join early on sector-defining innovation.
• Spot high-potential companies trading below their worth and take action with these 927 undervalued stocks based on cash flows, maximizing your shot at value investing wins.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com